ebomi
Colour theme
Sign in
Insider · CIK 0001746342

Chang Carmen

CIK 0001746342 Name as filed on the most recent filing

Filed as Chang Carmen (25)

34 transaction lines · from 25 filings · filed 2019-02-19 to 2026-03-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

33 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

Transactions filed by this insider
Direction Date Issuer Code Shares Price Value USD Filing
2026-03-10 Korro Bio, Inc.
KRRO 		P, Open-market purchase 207,100 acquired 11.11 2,300,881.00 Form 4, filing 0001193125-26-104717
2026-02-09 SpyGlass Pharma, Inc.
SGP 		P, Open-market purchase 937,500 acquired 16.00 15,000,000.00 Form 4, filing 0001193125-26-046663
2025-10-02 NeueHealth, Inc.
NEUE 		S, Open-market sale 2,455 disposed 6.75 16,571.25 Form 4, filing 0001193125-25-232142
2025-10-02 NeueHealth, Inc.
NEUE 		S, Open-market sale 900 disposed 6.75 6,075.00 Form 4, filing 0001193125-25-232142
2025-10-02 NeueHealth, Inc.
NEUE 		S, Open-market sale 280 disposed 6.75 1,890.00 Form 4, filing 0001193125-25-232142
2025-10-02 NeueHealth, Inc.
NEUE 		S, Open-market sale 280 disposed 6.75 1,890.00 Form 4, filing 0001193125-25-232142
2024-12-23 Marker Therapeutics, Inc.
MRKR 		P, Open-market purchase 554,250 acquired 3.20 1,773,600.00 Form 4, filing 0000950170-24-139630
2024-09-16 MBX Biosciences, Inc.
MBX 		P, Open-market purchase 500,000 acquired 16.00 8,000,000.00 Form 4, filing 0000950170-24-107552
2024-04-22 Korro Bio, Inc.
KRRO 		P, Open-market purchase 17,857 acquired 56.00 999,992.00 Form 4, filing 0000950170-24-047687
2023-07-17 Savara Inc
SVRA 		P, Open-market purchase 333,333 acquired 3.00 999,999.00 Form 4, filing 0001209191-23-042799
2023-03-15 Coursera, Inc.
COUR 		S, Open-market sale 1,226 disposed 11.82 14,496.59 Form 4, filing 0001209191-23-019642
2022-05-25 Genocea Biosciences, Inc.
GNCA 		S, Open-market sale 4,445,093 disposed 0.08 362,719.59 Form 4, filing 0001209191-22-032322
2022-05-24 Genocea Biosciences, Inc.
GNCA 		S, Open-market sale 5,931,843 disposed 0.07 387,942.53 Form 4, filing 0001209191-22-032322
2022-04-11 Trevi Therapeutics, Inc.
TRVI 		P, Open-market purchase 2,631,578 acquired 1.90 4,999,998.20 Form 4, filing 0001209191-22-024315
2022-04-11 Trevi Therapeutics, Inc.
TRVI 		P, Open-market purchase 948,948 acquired 1.90 1,803,001.20 Form 4, filing 0001209191-22-024315
2021-12-22 Metacrine, Inc.
MTCR 		S, Open-market sale 288,768 disposed 1.00 289,287.78 Form 4, filing 0001209191-21-071268
2021-12-22 Metacrine, Inc.
MTCR 		S, Open-market sale 170,932 disposed 0.91 155,565.21 Form 4, filing 0001209191-21-071268
2021-12-10 Metacrine, Inc.
MTCR 		S, Open-market sale 37,570 disposed 1.32 49,629.97 Form 4, filing 0001209191-21-071268
2021-10-18 Trevi Therapeutics, Inc.
TRVI 		P, Open-market purchase 1,851,852 acquired Not reported Not priced Form 4, filing 0001209191-21-061093
2021-06-28 Bright Health Group Inc.
BHG 		P, Open-market purchase 1,694,444 acquired 18.00 30,499,992.00 Form 4, filing 0001209191-21-044190
2021-06-28 Bright Health Group Inc.
BHG 		P, Open-market purchase 250,000 acquired 18.00 4,500,000.00 Form 4, filing 0001209191-21-044190
2021-06-28 Monte Rosa Therapeutics, Inc.
GLUE 		P, Open-market purchase 1,050,000 acquired 19.00 19,950,000.00 Form 4, filing 0001209191-21-044039
2021-03-16 Marker Therapeutics, Inc.
MRKR 		P, Open-market purchase 5,714,285 acquired 1.75 9,999,998.75 Form 4, filing 0001209191-21-021812
2020-12-04 Regulus Therapeutics Inc.
RGLS 		P, Open-market purchase 4,398,602 acquired 0.62 2,735,930.44 Form 4, filing 0001209191-20-061967
2020-09-18 Metacrine, Inc.
MTCR 		P, Open-market purchase 769,230 acquired 13.00 9,999,990.00 Form 4, filing 0001209191-20-051528
2020-07-24 Genocea Biosciences, Inc.
GNCA 		P, Open-market purchase 3,151,260 acquired 2.25 7,090,335.00 Form 4, filing 0001209191-20-043866
2020-06-30 Akouos, Inc.
AKUS 		P, Open-market purchase 588,235 acquired 17.00 9,999,995.00 Form 4, filing 0001209191-20-039826
2020-04-03 Trevi Therapeutics, Inc.
TRVI 		S, Open-market sale 564 disposed 2.66 1,500.24 Form 4, filing 0001209191-20-024283
2019-07-22 Mirum Pharmaceuticals, Inc.
MIRM 		P, Open-market purchase 450,000 acquired 15.00 6,750,000.00 Form 4, filing 0001209191-19-043056
2019-06-24 Genocea Biosciences, Inc.
GNCA 		P, Open-market purchase 2,857,142 acquired 3.50 9,999,997.00 Form 4, filing 0001209191-19-038956
2019-05-09 Trevi Therapeutics, Inc.
TRVI 		P, Open-market purchase 1,500,000 acquired 10.00 15,000,000.00 Form 4, filing 0001209191-19-029395
2019-05-09 Trevi Therapeutics, Inc.
TRVI 		P, Open-market purchase 1,000,000 acquired 10.00 10,000,000.00 Form 4, filing 0001209191-19-029395
2019-05-07 Regulus Therapeutics Inc.
RGLS 		P, Open-market purchase 1,136,704 acquired 1.08 1,227,640.32 Form 4, filing 0001209191-19-028594
2019-02-14 Genocea Biosciences, Inc.
GNCA 		P, Open-market purchase 9,948,269 acquired 0.47 4,688,619.18 Form 4, filing 0001209191-19-011157

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 22
  • Open-market sale 11
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Chang Carmen, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001746342

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.